The ISAD supports GADA’s initiative to collect global epidemiological data using appropriate instruments, which are not always readily available. This real-world data initiative should be encouraged, particularly given the significant information gaps in countries and regions with limited medical infrastructure. If you are interested in participating, please visit https://qualtrics.kcl.ac.uk/ On behalf of the Global Atopic […]
Read More
AD hidden hematologic risk: clonal hematopoiesis of indeterminate potential (CHIP)➜ DOI: 10.1111/all.16587Patients with AD exhibit a significant increased prevalence of CHIP, particularly affecting lymphoid-lineage genes. These findings suggest an underrecognized predisposition to hematologic malignancies in AD, warranting closer surveillance and mechanistic investigation. A recent Nature paper indicates that metformin could prevent CHIP development (DOI: 10.1038/s41586-025-08871-w) An [...] Read More
The success of the inaugural call for the ISAD-GADA Fellowship was highlighted, with nine applicants from nine different countries (Ethiopia, Tanzania, South Africa, Brazil, the Philippines, Nepal, Nigeria, China, and Uganda). A heartfelt thank you to everyone who applied. We were genuinely encouraged by the volume and quality of submissions we received. We are delighted […]
Read More
How COVID Quarantine May Have Fueled Infantile AD➜ DOI: 10.1111/all.16561Environmental exposures in early life are increasingly linked to the development of AD. China’s COVID-19 lockdown drastically altered infant environmental contact. This Shanghai birth cohort study examined 2204 mother–child pairs, comparing pre- and post-quarantine births. Infants exposed to early-life quarantine had significantly higher rates of AD by [...] Read More
Crusted Scabies and Dupilumab: A Case from Brazil➜ DOI: 10.25259/IJDVL_753_2024Crusted scabies is typically seen only in immunocompromised patients. This case from Brazil underscores the need for heightened vigilance in atopic dermatitis (AD) patients undergoing dupilumab treatment, particularly if they experience a sudden worsening of pruritus or lesions. More broadly, it highlights the risk of parasitic infections [...] Read More
Defining a good indication of nemoluzimab based on clinical criteria➜ DOI: 10.1111/1346-8138.17626Nemolizumab is an effective treatment for pruritus in atopic dermatitis, but it has a relatively high incidence of cutaneous adverse events (cAEs). To optimize the use of nemolizumab, Japanese researchers investigated the relationship between baseline severity in specific body areas and the frequency of cAEs. [...] Read More
Season of birth shapes human milk microbiome➜ DOI: 10.1111/all.16469In this Australian study, the season of infant birth emerged as the strongest determinant of the microbiome community structure with impacts on five of the most abundant taxa. This seasonal effect is not correlated with a bad taxon more prevalent in winter where AD is more common. The [...] Read More
Communication from GADA Kicking off the new year with exciting news! We’re thrilled to announce the upcoming launch of the ISAD-GADA Fellowship! This program is designed to support #earlycareer #dermatologists or researchers in #epidemiology and #publichealth, providing them with the opportunity to collaborate with the GADA team, acquire valuable skills, and lead a small GADA […]
Read More
Better spatial tissue imaging techniques to differentiate CTCL and AD➜ DOI: 10.1038/s41540-024-00474-xCutaneous T-cell lymphomas (CTCLs) can be difficult to distinguish from inflammatory skin conditions like atopic dermatitis (AD). Multi-antigen imaging protein abundance maps were analyzed with spatial graphs inferred from the cells' positions in the tissue samples. Characteristic patterns of skin tissue organization allowed a high-precision [...] Read More
Fecal microbiota transplantation (FMT): first RCT.➜ DOI: 10.1111/all.16372This Chinese randomized, double-blind, placebo-controlled clinical trial, studied the efficacy and safety assessment of FMT for moderate-to-severe adult patients with AD. All patients received FMT or placebo as capsules sourced for FMT verum from 2 strictly screened healthy donors once a week for 3 weeks, in addition to their [...] Read More